Pharmaceutical Technology
The EMA’s CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations.
Pharmaceutical Technology
The EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories' Braftovi to treat mCRC with BRAFV600E mutations.
Pharmaceutical Technology
The EMA’s CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations.